Form 4: PETIT ROBERT reports acquisition/exercise transactions in OSTX

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

PETIT ROBERT reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider PETIT ROBERT

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy)	100,000	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock options (right to buy) — 100,000 shares (Direct); Common Stock — 200,000 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

02/13/2026 - 04:41 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PETIT ROBERT

(Last)

(First)

(Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE

21638

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock options (right to buy)	$1.34	01/22/2026		A		100,000		⁽¹⁾	01/22/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. On January 22, 2026, the reporting person was granted options to purchase 100,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date.

Remarks:

Robert Petit is the Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated.

	/s/ Robert Petit	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did OS Therapies (OSTX) report for Robert Petit?

OS Therapies reported that Chief Medical Officer and Chief Scientific Officer Robert Petit received a grant of stock options for 100,000 shares. The options were awarded on January 22, 2026, and give him the right to buy OS Therapies common stock at a fixed exercise price.

What are the terms of Robert Petit’s 100,000 OS Therapies (OSTX) stock options?

Robert Petit’s grant covers options to purchase 100,000 shares of OS Therapies common stock at an exercise price of $1.34 per share. The options expire on January 22, 2036 and vest in full one year after the grant date, contingent on his continued employment.

When do Robert Petit’s OS Therapies (OSTX) stock options vest?

The options granted to Robert Petit vest in full on the one-year anniversary of the January 22, 2026 grant date. Vesting requires that he is serving as an employee of OS Therapies on that anniversary, aligning the award with his continued service to the company.

How many OS Therapies (OSTX) shares does Robert Petit beneficially own after the reported Form 4?

After the reported transactions, Robert Petit directly beneficially owned 200,000 shares of OS Therapies common stock. This figure reflects his reported non-derivative holdings following the option grant and is separate from the 100,000 stock options disclosed as a derivative security award.

What role does Robert Petit hold at OS Therapies (OSTX)?

Robert Petit serves as Chief Medical Officer and Chief Scientific Officer at OS Therapies Incorporated. His leadership roles are highlighted in the filing’s remarks, and the stock option grant was made under a stock option award agreement tied to his continued employment with the company.

What type of transaction code applies to Robert Petit’s OS Therapies (OSTX) option grant?

The stock option grant to Robert Petit is reported with transaction code “A,” which indicates a grant, award, or other acquisition of derivative securities. This code clarifies that the transaction is an award of options rather than an open-market purchase or sale of existing shares.